2 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 8 Phase 3, 2 Phase 2.
By phase and status
Follow PLD: new trials by email Literature Review of PLD trials Research Report on PLD
Trials (filtered) newest first · largest first
All 8 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer Phase 3 Recruiting 688 2026-08-28 2026-10-07 Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) NP-G2-044, PLD - Platinum-resistant Ovarian Cancer Phase 2 / Phase 3 Active not recruiting 380 2025-12-29 2026-03-09 A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer R-DXd, Paclitaxel, Topotecan - Solid Cancer Phase 2 / Phase 3 Recruiting 860 2024-02-27 2026-10-26 Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer Carboplatin, Gemcitabine, Bevacizumab - Recurrent Ovarian Carcinoma Phase 3 Terminated 9 2019-08-09 2022-02-24 Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma Cyclophosphamide, pegylated liposomal doxorubicin, Vincristine - Peripheral T-cell Lymphoma Phase 3 Unknown 244 2019-05-10 2019-05-16 Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD) PLD, CTX, Docetaxel - Early Breast Cancer Phase 3 Unknown 272 2017-09-01 2019-05-14 A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) avelumab, PLD - Ovarian Cancer Phase 3 Completed 566 2015-12-21 2023-07-10 Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer Carboplatin, PLD, Bevacizumab - Recurrent Platinum-sensitive Ovarian Cancer Phase 3 Completed 682 2013-05-01 2021-07-13
Conditions studied Ovarian Neoplasms (6) · Breast Neoplasms (1) · Fallopian Tube Neoplasms (1) · Lymphoma, T-Cell, Peripheral (1)
Sponsors AGO Research GmbH (2) · Daiichi Sankyo (1) · Fudan University (1) · Genmab (1) · Novita Pharmaceuticals, Inc. (1) · Peking University (1) · Pfizer (1)
Countries United States (4) · Australia (3) · China (3) · France (3) · Germany (3) · Japan (3) · United Kingdom (3) · Austria (2) · Belgium (2) · Canada (2) · Czechia (2) · Greece (2) · Italy (2) · Poland (2) · South Korea (2)
Top investigators Felix Hilpert, MD, PhD (1) · Jacobus Pfisterer, PhD MD (1) · Jillian Zhang, PhD (1) · Jun Zhu, PHD (1) · Lisa Barroilhet, MD (1)
Results publications PMID 32305099 , PMID 34143970 , PMID 37407274 , PMID 37665777 , PMID 40504550
NIH funding 2015 (1) , 2025 (1)